InsidersTradesSigma
Total declarations
Company
▲ Purchases (32 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Sumitomo Chemical Co., Ltd., Representative Director & President. Officer active across 1 companies, notably Myovant Sciences Ltd.. In total, 32 filings have been published. Total volume traded: €25.9m. The latest transaction was disclosed on 28 September 2021 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations32 total
€404,21820,677 shares@ €19.54923.1% of flow
Common Stock
SEC:0000899243-21-038387·
Ideal exit: 25 Jun 2022 (T+270)
€404,21820,677 shares@ €19.54921.6% of flow
Common Stock
SEC:0000899243-21-038387:0·
Ideal exit: 25 Jun 2022 (T+270)
€717,65736,000 shares@ €19.93495.5% of flow
Common Stock
SEC:0000899243-21-038083·
Ideal exit: 21 Jun 2022 (T+270)
€717,65736,000 shares@ €19.93492.8% of flow
Common Stock
SEC:0000899243-21-038083:0·
Ideal exit: 21 Jun 2022 (T+270)
€2m84,018 shares@ €18.788712.2% of flow
Common Stock
SEC:0000899243-21-037631·
Ideal exit: 19 Jun 2022 (T+270)
€2m84,018 shares@ €18.78876.1% of flow
Common Stock
SEC:0000899243-21-037631:0·
Ideal exit: 19 Jun 2022 (T+270)
€720,93338,273 shares@ €18.83665.6% of flow
Common Stock
SEC:0000899243-21-037114·
Ideal exit: 17 Jun 2022 (T+270)
€720,93338,273 shares@ €18.83662.8% of flow
Common Stock
SEC:0000899243-21-037114:0·
Ideal exit: 17 Jun 2022 (T+270)
€924,20050,000 shares@ €18.4847.1% of flow
Common Stock
SEC:0000899243-21-036597·
Ideal exit: 13 Jun 2022 (T+270)
€924,20050,000 shares@ €18.4843.6% of flow
Common Stock
SEC:0000899243-21-036597:0·
Ideal exit: 13 Jun 2022 (T+270)
€1m65,128 shares@ €18.66779.4% of flow
Common Stock
SEC:0000899243-21-036290·
Ideal exit: 11 Jun 2022 (T+270)
€1m65,128 shares@ €18.66774.7% of flow
Common Stock
SEC:0000899243-21-036290:0·
Ideal exit: 11 Jun 2022 (T+270)
€637,06730,000 shares@ €21.23564.9% of flow
Common Stock
SEC:0000899243-21-035821·
Ideal exit: 7 Jun 2022 (T+270)
€637,06730,000 shares@ €21.23562.5% of flow
Common Stock
SEC:0000899243-21-035821:0·
Ideal exit: 7 Jun 2022 (T+270)
€476,90921,902 shares@ €21.77473.7% of flow
Common Stock
SEC:0000899243-21-035564·
Ideal exit: 5 Jun 2022 (T+270)
€476,90921,902 shares@ €21.77471.8% of flow
Common Stock
SEC:0000899243-21-035564:0·
Ideal exit: 5 Jun 2022 (T+270)
€671,39729,822 shares@ €22.51355.2% of flow
Common Stock
SEC:0000899243-21-035342·
Ideal exit: 31 May 2022 (T+270)
€671,39729,822 shares@ €22.51352.6% of flow
Common Stock
SEC:0000899243-21-035342:0·
Ideal exit: 31 May 2022 (T+270)
€838,64240,000 shares@ €20.9666.5% of flow
Common Stock
SEC:0000899243-21-035135·
Ideal exit: 29 May 2022 (T+270)
€838,64240,000 shares@ €20.9663.2% of flow
Common Stock
SEC:0000899243-21-035135:0·
Ideal exit: 29 May 2022 (T+270)
€1m70,000 shares@ €20.272911.0% of flow
Common Stock
SEC:0000899243-21-034765·
Ideal exit: 27 May 2022 (T+270)
€1m70,000 shares@ €20.27295.5% of flow
Common Stock
SEC:0000899243-21-034765:0·
Ideal exit: 27 May 2022 (T+270)
€771,41940,000 shares@ €19.28556.0% of flow
Common Stock
SEC:0000899243-21-034525·
Ideal exit: 23 May 2022 (T+270)
€771,41940,000 shares@ €19.28553.0% of flow
Common Stock
SEC:0000899243-21-034525:0·
Ideal exit: 23 May 2022 (T+270)
€652,82334,299 shares@ €19.03335.0% of flow
Common Stock
SEC:0000899243-21-034281·
Ideal exit: 21 May 2022 (T+270)
25 of 32 declarations
About Sumitomo Chemical Co., Ltd.
Nobuaki Mito is a long-tenured executive at Sumitomo Chemical Co., Ltd., having joined the company in 1985. His career reflects a steady internal rise through a large Japanese industrial group, with expanding responsibilities in both governance and operations. He became an Executive Officer in 2015, Managing Executive Officer in 2018, Representative Director & Managing Executive Officer in 2020, and Representative Director & Senior Managing Executive Officer in 2021. In 2025, he was promoted to President and then Representative Director & President. ([sumitomo-chem.co.jp](https://www.sumitomo-chem.co.jp/english/company/executives/?utm_source=openai)) In his recent assignments, he has been linked to the Advanced Medical Solutions sector, underscoring the strategic importance of healthcare and life-sciences activities within the group. Sumitomo Chemical also emphasizes a formal governance framework centered on the board of directors, the Audit & Supervisory Committee, and internal control mechanisms, within which the president plays a central role in executing strategy, capital allocation, and portfolio management. ([sumitomo-chem.co.jp](https://www.sumitomo-chem.co.jp/english/company/executives/?utm_source=openai)) At the company level, the broader leadership environment has been associated with ongoing work in advanced materials, digital transformation, and bioscience-related businesses. Sumitomo Chemical has pursued targeted investments and acquisitions in agriculture and biotechnology, alongside initiatives in recycled materials and bio-based manufacturing. These moves point to a long-term strategy focused on innovation, sustainability, and value creation across global markets. ([sumitomo-chem.co.jp](https://www.sumitomo-chem.co.jp/english/news/detail/20250612e.html?utm_source=openai)) His connection to Myovant Sciences Ltd. sits within Sumitomo’s North American life-sciences and healthcare investment ecosystem. Without inventing unverified specifics, the most accurate characterization is that of an experienced industrial leader with substantial exposure to diversified business portfolios, organizational change, and high-governance corporate settings in an international context. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1679082/000114036123000812/ny20005635x8_sc13e3a.htm?utm_source=openai))
